Date: 2013-02-27
Type of information: Grant
Company: Mission Therapeutics (UK)
Investors: BioMedical Catalyst Fund (UK)
Amount:
Funding type: grant
Planned used: The funds from this award will be used to screen all known deubiquitylating enzymes to find those which are suitable targets for Mission\'s drug development programmes.
Others: * On February 27, 2013, Mission Therapeutics, a UK-based company focused on the discovery and development of modulators of deubiquitylating enzymes (DUBs) for the treatment of cancer, has been granted a Biomedical Catalyst Feasibility Award by the Technology Strategy Board to support the identification of DUBs required for the survival of drug-resistant ovarian cancers. Using an innovative approach, MISSION will identify novel DUB targets by exploiting the very changes in tumours that led to the development of drug resistance.
The funds from this award will be used to screen all known deubiquitylating enzymes to find those which are suitable targets for Mission\'s drug development programmes. The project will see Mission identify DUB targets whose inhibition selectively kills drug-resistant ovarian tumours or re-sensitises them to chemotherapy. The most promising targets will enter MISSION’s pipeline for further drug discovery efforts with a view to developing new therapeutic agents for ovarian cancer. Funded for a year, the project will be directed by Dr Helen Robinson, Team Leader and Dr Xavier Jacq, Head of Biology.
Therapeutic area: Cancer - Oncology
